Wall Street closes at a record for the first time since end of January
Investing.com - H.C. Wainwright reiterated a Buy rating and $12.00 price target on Microbot Medical (NASDAQ:MBOT) following the company’s announcement of its full market release in the U.S. The stock currently trades at $2.35 with a market cap of $157.82 million, up 17.5% year-to-date.
Microbot Medical announced Monday that it successfully executed the limited market release of the LIBERTY system and is commencing full market release in the U.S. at the Society of Interventional Radiology annual scientific meeting in Toronto, Canada from April 11-15, 2026. The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic system.
During the limited market release, LIBERTY was adopted by multiple healthcare systems and used across procedures including Prostate Artery Embolization, Uterine Fibroid Embolization, Genicular Artery Embolization, Y90 mapping, Y90 deliveries, and peripheral arterial interventions. The rapid customer adoption during limited market release shows that LIBERTY has a shorter sales cycle compared to traditional surgical robots. An InvestingPro tip notes the company holds more cash than debt on its balance sheet, though analysts don’t anticipate profitability this year. According to InvestingPro’s Fair Value analysis, the stock appears overvalued at current levels.
At the SIR meeting, the company plans to target end users in attendance and engage with them directly. Microbot is broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories across the U.S. by the end of 2026.
The initial addressable market comprises approximately 2.5 million peripheral endovascular procedures each year in the U.S.
In other recent news, Microbot Medical Inc. announced the full market release of its LIBERTY Endovascular Robotic System in the United States, following a successful limited market release. The system has been adopted by healthcare systems including Emory Healthcare and Tampa General Hospital, and is used in various procedures such as Prostate Artery Embolization and Uterine Fibroid Embolization. Emory Healthcare recently completed robotic procedures using the LIBERTY system, marking the first robotic prostate artery embolization for benign prostatic hyperplasia. Additionally, a study evaluating the LIBERTY system was published in the Journal of Vascular and Interventional Radiology, highlighting its feasibility for arterial peripheral vascular interventions.
Microbot Medical has also emphasized the LIBERTY system’s ability to address radiation exposure concerns, aligning with new protective policies adopted by the American Medical Association. The company stated that its operations in the United States and Israel remain unaffected by geopolitical events in the Middle East, ensuring continued manufacturing and commercial activities. These developments reflect Microbot Medical’s ongoing efforts to expand its market presence and address industry challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.